Alvotech Submits Biosimilar Application for Retinal Disease Treatment to EMA
What happened
Alvotech submitted AVT29 to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli®. AVT29 is a proposed biosimilar to Eylea® 8 mg, which is used to treat certain retinal diseases. This submission marks the first worldwide regulatory application for a biosimilar to Eylea® 8mg.
From manilatimes.net
Why it matters
The submission introduces a biosimilar competitor to Eylea® 8 mg, which is used for retinal diseases. If approved, the availability of this biosimilar could increase competition in the market, potentially affecting treatment costs and frequency for patients.
From manilatimes.net
Who's involved
- AlvotechBiotechnology company that filed the regulatory application for AVT29.
- European Medicines AgencyEuropean regulatory authority receiving the application for product approval.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AlvotechSpeculative
The company might see changes in sales volume and market share if the application is approved.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- European Commission must review new high-dose biosimilar applicationEuropean Commission must review new high-dose biosimilar applicationLikely
- New high-dose biosimilar may expand treatment options in the EEANew high-dose biosimilar could expand treatment options within the EEA.Possible
- Alvotech's biosimilar application may challenge Incyte's market positionAlvotech's biosimilar submission could increase competition in retinal disease treatmentPossible
Keep exploring
The entities involved
-
Alvotech
biotechnology company
Nothing else this week.
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
- PolyPid Ltd's product received FDA Priority Review and gained single authorization across EU states from the EMA.